Specialty Pharmacy

Gecacitinib is a novel inhibitor targeting both JAK and ACVR1.

Adoption barriers include insurance coverage, patient and provider education, and regulatory hurdles that require aligned initiatives across stakeholders.

Pharmacists can significantly improve chronic obstructive pulmonary disease (COPD) management by promoting non-pharmacological interventions.

Despite the explosion of public interest in these drugs, ongoing shortages and debates over compounding made access difficult.

Currently available for prescription in the United States, vibegron is now the first and only β3 agonist FDA approved to treat patients living with OAB and being treated for BPH.

Concizumab-mtci is a subcutaneous, monoclonal antibody designed to achieve hemostasis in all hemophilia types.

The medication, glepaglutide, is in development for the treatment of adults with short bowel syndrome with intestinal failure who are dependent on parenteral support.

The approval comes after clinical trial results in which vanzacaftor/tezacaftor/deutivacaftor (Alyftrek; Vertex Pharmaceuticals) demonstrated superiority compared with elexacaftor/tezacaftor/ivacaftor and ivacaftor (Trikafta; Vertex Pharmaceuticals).

Vanzacaftor/tezacaftor/deutivacaftor (Alyftek) also received approval for the treatment of cystic fibrosis in people 6 years and older who have at least 1 F508del mutation.

Setmelanotide is indicated to reduce excess body weight and maintain weight reduction long-term for patients with syndromic or monogenic obesity due to Bardet-Biedl syndrome.

Compounding pharmacies have a 60- to 90-day grace period to complete production as it continues to monitor supply and demand.

Compounding pharmacies play a vital role in meeting the unique needs of patients, but pharmacists must adhere to strict safety standards and regulations.

The rare genetic disease is a severe hypertriglyceridemia that can lead to potentially life-threatening acute pancreatitis.

The evolving regulatory policies around biosimilar interchangeability is crucial for driving successful biosimilar adoption in the marketplace.

Pharmacy errors can happen due to manual processes, but they can be mitigated through adoption of automated IV workflow technology and comprehensive compounding records.

Standardizing observational competencies and utilizing technology to improve compounding accuracy can ensure safety and quality of compounded medications.

The tool is designed to address the nocebo effect, which was a concern of prescribers and other health care professionals.

Based on positive results from the HERCULES trial, the new designation will allow for more thorough regulatory review and development of the multiple sclerosis treatment.

Daily operational tasks and quality assurance measures in pharmacy compounding ensures patient safety and maintains compliance.

Pharmacists can help drive the successful adoption of biosimilars by developing educational programs to address provider and patient concerns.

The full results will be published in a peer-reviewed journal and presented at a medical meeting next year as the full results are evaluated.

According to the report, 75% of survey participants expect pharmacists to oversee these therapies and 58% expect Medicare will require pharmacist involvement.

The addition of samidorphan can support the antipsychotic efficacy of olanzapine while mitigating associated weight gain.

Fabry disease is a rare lysosomal disorder that causes excessive deposition of lipids in tissues.

The treatment is a type IA prodrug of dexamethasone that targets CD206+ macrophages.

Clinicians' enthusiasm for cell and gene therapies is tempered by practical concerns.

The study also found that HSSPs minimize health costs and provide additional revenue for health systems.

A vast majority of patients achieved a positive clinical response with the combination, with improvements in their ocular condition.

Investigators presented additional data from a clinical trial at the American College of Rheumatology Convergence, demonstrating similar safety for postmenopausal women with osteoporosis.

The biosimilar is approved for the treatment of Crohn disease, ulcerative colitis, plaque psoriasis, and psoriatic arthritis.